Teva

This sponsor has funded 40 studies across 20 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
5171 Finalised Characteristics of asthma patients at risk of failed Diskus use in primary care: a retrospective cohort study No No
7645 Ongoing Comparative effectiveness and safety of Salbutamol Sterinebs® vs Ventolin Nebules® in COPD patients. No No
7678 Finalised COMPARATIVE EFFECTIVENESS AND SAFETY OF BUDESONIDE STERINEBS® VS. PULMICORT RESPULES® IN A US POPULATION OF ASTHMA PATIENTS. Yes No
7744 Ongoing The use of a spacer in the delivery of large (Fluticasone Propionate) and small particle (Qvar®) inhaled corticosteroid (ICS) in asthma (FP and Qvar... No No
7753 Finalised Comparative effectiveness and safety of Ipramol (ipratropium/albuterol) SteriNebs® vs. DuoNeb® Yes No
8019 Finalised Characterising patients at risk of failed Diskus use in primary care Yes No
8391 Finalised Real-world effectiveness of extrafine vesrus standard particle inhaled corticosteroids: A comparative effectiveness analysis of extrafine (EF)... Yes No
8740 Finalised State of the Union: Current asthma morbidity in the UK No No
8832 Finalised A real-life historic study assessing metabolic and other adverse effects of small versus large particle inhaled corticosteroids in relation to their... No No
8840 Finalised Dose response curves for patients prescribed small & large particle ICS formulation: an observational evaluation of the comparative effect of ICS dose... No No
9105 Ongoing Real-world effectiveness of extra-fine formulations in Denmark No No
9651 Finalised CRITIKAL Study Yes No
10402 Finalised Pharmaco-epidemiologic study on occurrence of adverse events No Yes
10559 Finalised Effectiveness of prescribing similar vs dissimilar devices for COPD management (phase 1) Yes No
10923 Finalised Effectiveness of prescribing similar vs dissimilar devices for COPD management (phase 2) Yes No
11391 Finalised Drug utilisation study (DUS) on flupirtine-containing products Retrospective drug utilisation study using patient-level databases to characterise... No Yes
11512 Finalised The role of adherence to inhaled corticosteroids in the relationship between blood eosinophilia and asthma control No No
11571 Finalised Post-Authorisation Safety Study (PASS) on Flupirtine-containing Medicinal Products - A retrospective, multicentre, non-interventional study to... No Yes
12030 Finalised A Cross-sectional Study to Evaluate the Effectiveness of the Colobreathe Risk Minimisation Educational Programme Among Healthcare Professionals and... No No
12321 Planned Training requirements to master inhaler devices available in real-life clinical practice (TMID) Yes No
12762 Finalised Incidence of oral thrush in COPD patients prescribed ICS as part of ICS/LABA therapy Yes No
12984 Ongoing Prescribing Patterns of Lipegfilgrastim (Lonquex®) in the European Union No No
13238 Finalised Real-life effectiveness evaluation of budesonide/formoterol (BF) Spiromax for the management of asthma and COPD Yes Yes
16395 Finalised An Open-label Observational Safety Study of Colobreathe® (colistimethate sodium dry powder for inhalation) Compared with Other Inhaled... No No
18976 Finalised A retrospective longitudinal cohort study assessing the safety of Seasonique® use: A post-marketing authorization safety study (PASS) to assess the... Yes Yes
19909 Finalised Risk of Melanoma Among Parkinson’s Disease Patients (TV1030-CNS-50024) No Yes
23021 Ongoing Assessment of pregnancy outcomes in patients treated with reslizumab: Active pregnancy surveillance No No
34763 Ongoing A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in... No No
35111 Planned Pan European Prospective Observational Study of Fremanezumab effectiveness in patients with chronic or episodic migraine in the Real-World, PEARL... No No
36320 Ongoing A Post-Authorisation Long-Term Retrospective Safety Cohort Study of Arsenic Trioxide in First Line Low- to Intermediate-Risk Acute Promyelocytic... No No
38434 Ongoing Assessment of pregnancy outcomes in patients treated with Ajovy (fremanezumab): pregnancy database study No No
38442 Ongoing Assessment of pregnancy outcomes in patients treated with Ajovy (fremanezumab): pregnancy registry (Teva migraine pregnancy registry) No No
41590 Finalised A Randomized, Placebo-Controlled, Parallel-Design, Exploratory Study to Evaluate the Efficacy of fremanezumab in Subjects with Rosacea No No
43538 Ongoing Assessment of Pregnancy Outcomes in Women Exposed to Modafinil/Armodafinil: Pregnancy Database Study No No
44465 Finalised Real-world safety of Copaxone in Offsprings of Breastfeeding and treated RMS pAtients – COBRA study Yes Yes
44516 Finalised Barriers to Care in Migraine in Germany No No
44606 Ongoing Prospective observational study of Fremanezumab (Ajovy™) effectiveness in chronic and episodic migraine patients in clinical routine: FINESSE study No No
50402 Planned A Long-Term Observational, Retrospective Cohort Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with... No No
103511 Ongoing An Open-Label, Single-Dose Study to Assess the Pharmacokinetics and Target Engagement in Cerebral Spinal Fluid and Plasma Following a Single... No No
105202 Planned Effectiveness and safety of rivaroxaban and amlodipine dual therapy compared to phenprocoumon and amlodipine dual therapy in non-valvular atrial... No No

PAS by Risk Management Plan (RMP) requirement

Teva

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.